Clinical Study

Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections

Table 3

Subgroup analysis of eradication rate.

Group (n)Intention-to-treat analysisPer protocol analysis
Eradication rate,
n (%)
Relative risk95% CI valueEradication rate,
n (%)
Relative risk95% CI value

Total75 (84.5)71 (88.8)
Age0.9471.000
 <60 years old43 (84.3)1.0350.370–2.89443 (89.6)1.0240.870–1.205
 ≥60 years old28 (84.8)0.9940.825–1.19728 (87.5)0.8330.242–2.869
Gender0.6501.000
 Male28 (82.4)0.9580.791–1.16028 (87.5)0.9770.830–1.149
 Female43 (86.0)1.2610.464–3.42543 (89.6)1.2000.349–4.132
BMI0.0640.032
 Normal BMI43 (91.5)1.2320.995–1.52543 (95.6)1.2131.005–1.464
 Overweight BMI26 (74.3)0.3310.111–0.98826 (78.8)0.2100.046–0.945
Alcohol0.2810.676
 Drinker17 (94.4)3.2790.455–23.52216 (94.4)2.3230.311–17.361
 Nondrinker54 (81.8)0.8660.738–1.01655 (87.1)0.9220.796–1.069
Smoking1.0001.000
 Smoker10 (90.9)1.2680.260–12.57010 (90.9)1.2750.176–9.229
 Nonsmoker61 (83.6)0.9190.743–1.13761 (88.4)0.9720.792–1.194
NSAIDs or
antithrombotic
agents
0.6030.220
 Yes6 (75)0.5790.155–2.1656 (75)0.3890.097–1.564
 No65 (85.5)1.1400.756–1.71965 (90.3)1.2040.801–1.809
HTN0.2030.476
 Yes27 (93.1)2.9000.689–12.21527 (93.1)1.9900.442–8.954
 No44 (80.0)0.8590.728–1.01444 (86.3)0.9270.799–1.074
DM1.0001.000
 Yes7 (87.5)1.2630.188–8.4927 (87.5)0.8890.127–6.225
 No64 (84.2)0.9620.728–1.27364 (88.9)1.0160.772–1.337
CVA0.0630.033
 Yes1 (33.3)0.2060.078–0.5441 (33.3)0.1380.048–0.402
 No69 (86.3)2.5880.521–12.85169 (90.8)2.7240.549–13.516
Liver disease1.0000.523
 Yes5 (83.3)0.9230.143–5.9505 (83.3)0.6490.097–4.359
 No66 (84.6)1.0150.701–1.47066 (89.2)1.0700.742–1.544
PUD1.0001.000
 Yes18 (85.7)1.0190.830–1.25118 (90)1.0190.857–1.211
 No53 (84.1)0.9000.273–2.96453 (88.3)0.8570.194–3.795

CI: confidence interval; BMI: body mass index; NSAIDs: nonsteroidal anti-inflammatory drugs; HTN: hypertension; DM: diabetes mellitus; CVA: cerebrovascular accident; PUD: peptic ulcer disease. .